Of the inherited prostate cancers, approximately 5.3% contain BRCA2 and 0.9% contain BRCA1 mutations making these subsets of prostate cancer ideal targets for PARP inhibitor therapy (Messina et al., 2020). This evidence concerns the gene PARP1 and prostate carcinoma.